Iterum Therapeutics Enters Material Definitive Agreement
Ticker: ITRM · Form: 8-K · Filed: Aug 4, 2025 · CIK: 1659323
| Field | Detail |
|---|---|
| Company | Iterum Therapeutics PLC (ITRM) |
| Form Type | 8-K |
| Filed Date | Aug 4, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, pharmaceuticals
TL;DR
Iterum Therapeutics just signed a big deal, details to follow.
AI Summary
On July 29, 2025, Iterum Therapeutics plc entered into a material definitive agreement. The company, incorporated in Ireland with its principal executive offices in Dublin, is involved in the pharmaceutical preparations industry.
Why It Matters
This filing indicates a significant new contract or partnership for Iterum Therapeutics, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The nature of the material definitive agreement is not specified, leaving uncertainty about its terms and potential impact.
Key Players & Entities
- Iterum Therapeutics plc (company) — Registrant
- July 29, 2025 (date) — Date of earliest event reported
- Ireland (location) — State of Incorporation
- Dublin (location) — Address of Principal Executive Offices
FAQ
What is the nature of the material definitive agreement entered into by Iterum Therapeutics plc?
The filing does not specify the nature of the material definitive agreement.
When was the material definitive agreement entered into?
The material definitive agreement was entered into on July 29, 2025.
What is Iterum Therapeutics plc's primary industry?
Iterum Therapeutics plc is in the Pharmaceutical Preparations industry, SIC code 2834.
Where are Iterum Therapeutics plc's principal executive offices located?
Iterum Therapeutics plc's principal executive offices are located at 25 North Wall Quay, Dublin 1, Ireland.
What is the Commission File Number for Iterum Therapeutics plc?
The Commission File Number for Iterum Therapeutics plc is 001-38503.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on August 4, 2025 regarding Iterum Therapeutics plc (ITRM).